In further support of the clinical relevance of ITGA11+/ENG+ stromogenic vs. non-stromogenic tumors, we observed that progression-free survival (PFS) of patients with pathological tumor stage ≥ T2c was significantly higher for those with tumors expressing high levels of SMC markers compared to those with lower expression of SMC markers (Fig. 3E, Supplemental Fig. S10H-I). The gene discussed is ITGA11; the disease is neoplasm.